Aisling Capital Management as of June 30, 2024
Portfolio Holdings for Aisling Capital Management
Aisling Capital Management holds 15 positions in its portfolio as reported in the June 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Bridgebio Pharma (BBIO) | 66.5 | $154M | 6.1M | 25.33 | |
| Syndax Pharmaceuticals (SNDX) | 9.1 | $21M | 1.0M | 20.53 | |
| Verona Pharma Sponsored Ads (VRNA) | 7.0 | $16M | 1.1M | 14.46 | |
| Elevation Oncology (ELEV) | 3.3 | $7.7M | 2.8M | 2.70 | |
| Nuvation Bio Com Cl A (NUVB) | 3.2 | $7.4M | 2.5M | 2.92 | |
| Compass Pathways Sponsored Ads (CMPS) | 2.5 | $5.8M | 965k | 6.04 | |
| Monte Rosa Therapeutics (GLUE) | 2.4 | $5.5M | 1.5M | 3.74 | |
| Biomea Fusion (BMEA) | 1.6 | $3.6M | 799k | 4.50 | |
| Poseida Therapeutics I (PSTX) | 1.3 | $3.0M | 1.0M | 2.92 | |
| CalciMedica Com New (CALC) | 0.9 | $2.1M | 521k | 3.96 | |
| Marker Therapeutics Com New (MRKR) | 0.7 | $1.7M | 314k | 5.43 | |
| Tectonic Therapeutic (TECX) | 0.6 | $1.4M | 84k | 16.47 | |
| Reneo Pharmaceuticals (RPHM) | 0.6 | $1.3M | 886k | 1.51 | |
| Aclaris Therapeutics (ACRS) | 0.2 | $478k | 435k | 1.10 | |
| Viracta Therapeutics (VIRX) | 0.1 | $157k | 289k | 0.54 |
